Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 10/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3142589 | 0.97 | LMNA (0.47) | LMNASMN1; SMN2ALDH1A1USP2PKM | |
| SCHEMBL3026272 | 0.90 | ABCB1 (0.43) | LMNASMN1; SMN2ALDH1A1USP2HTT | |
| SCHEMBL3027481 | 0.84 | ABCB1 (0.48) | LMNASMN1; SMN2ALDH1A1USP2HTT | |
| SCHEMBL3133427 | 0.81 | SMN1; SMN2 (0.46) | LMNASMN1; SMN2ALDH1A1USP2PKM | |
| SCHEMBL3033606 | 0.81 | CYP3A4 (0.43) | LMNASMN1; SMN2ALDH1A1USP2HTT | |
| SCHEMBL3036162 | 0.81 | MEN1 (0.46) | LMNASMN1; SMN2ALDH1A1USP2HTT | |
| SCHEMBL3133508 | 0.81 | LMNA (0.48) | LMNASMN1; SMN2ALDH1A1USP2PKM | |
| SCHEMBL3135150 | 0.80 | LMNA (0.46) | LMNASMN1; SMN2ALDH1A1USP2PKM | |
| SCHEMBL3026304 | 0.79 | HIF1A (0.48) | LMNASMN1; SMN2ALDH1A1USP2HSD17B10 | |
| SCHEMBL12315676 | 0.77 | TDP1 (0.54) | LMNASMN1; SMN2ALDH1A1HTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957073-B1 | MEDICINAL DRUG | OTSUKA PHARMA CO LTD (JP) | 2014-04-23 | — | — | EP | disclosed |
| US-20120238750-A1 | AROMATIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-09-20 | — | — | US | disclosed |
| US-8236826-B2 | Diarylether derivatives as antitumor agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| US-8188277-B2 | Aromatic compounds for suppressing the generation of collagen | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-1957073-A2 | MEDICINAL DRUG | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-08-20 | — | — | EP | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| WO-2007066784-A2 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | WO | disclosed |
| EP-1773797-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006014012-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238750-A1 | AROMATIC COMPOUND | CBR1, CBR3, CYP1A1 | LMNA 2721/4885SMN1; SMN2 4313/4885ALDH1A1 565/4885 |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | ROS1, CBR1, CBR3 | LMNA 4340/4885SMN1; SMN2 3224/4885ALDH1A1 265/4885 |
| US-20070270422-A1 | Aromatic Compounds | COL1A1, COL2A1, COL14A1 | LMNA 1091/4885SMN1; SMN2 3077/4885ALDH1A1 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.